

# Manuel Alfonso Patarroyo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11915857/publications.pdf>

Version: 2024-02-01

29  
papers

588  
citations

623734

14  
h-index

610901

24  
g-index

29  
all docs

29  
docs citations

29  
times ranked

620  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural and Immunological Principles Leading to Chemically Synthesized, Multiantigenic, Multistage, Minimal Subunit-Based Vaccine Development. <i>Chemical Reviews</i> , 2011, 111, 3459-3507.	47.7	93
2	Genetic polymorphism of the Duffy receptor binding domain of <i>Plasmodium vivax</i> in Colombian wild isolates. <i>Molecular and Biochemical Parasitology</i> , 1996, 78, 269-272.	1.1	75
3	Distribution Patterns of Infection with Multiple Types of Human Papillomaviruses and Their Association with Risk Factors. <i>PLoS ONE</i> , 2011, 6, e14705.	2.5	42
4	A highly infective <i>Plasmodium vivax</i> strain adapted to Aotus monkeys: Quantitative haematological and molecular determinations useful for <i>P. vivax</i> malaria vaccine development. <i>Vaccine</i> , 2003, 21, 3930-3937.	3.8	38
5	The DNA load of six high-risk human papillomavirus types and its association with cervical lesions. <i>BMC Cancer</i> , 2015, 15, 100.	2.6	36
6	<i>Plasmodium falciparum</i> pre-erythrocytic stage vaccine development. <i>Malaria Journal</i> , 2020, 19, 56.	2.3	36
7	Detection by PCR of human papillomavirus in Colombia: Comparison of GP5+/6+ and MY09/11 primer sets. <i>Journal of Virological Methods</i> , 2011, 178, 68-74.	2.1	35
8	IMPIPS: The Immune Protection-Inducing Protein Structure Concept in the Search for Steric-Electron and Topochemical Principles for Complete Fully-Protective Chemically Synthesised Vaccine Development. <i>PLoS ONE</i> , 2015, 10, e0123249.	2.5	25
9	Functional, structural, and immunological compartmentalisation of malaria invasive proteins. <i>Biochemical and Biophysical Research Communications</i> , 2007, 354, 363-371.	2.1	22
10	Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans. <i>Biochemical and Biophysical Research Communications</i> , 2017, 491, 1062-1069.	2.1	20
11	Mce4F <i>Mycobacterium tuberculosis</i> protein peptides can inhibit invasion of human cell lines. <i>Pathogens and Disease</i> , 2015, 73, .	2.0	17
12	<i>Plasmodium falciparum</i> Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines. <i>Frontiers in Microbiology</i> , 2019, 10, 2712.	3.5	17
13	Major Histocompatibility Complex Class II (DRB3) Genetic Diversity in Spanish Morucha and Colombian Normande Cattle Compared to Taurine and Zebu Populations. <i>Frontiers in Genetics</i> , 2020, 10, 1293.	2.3	16
14	Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization. <i>Vaccine</i> , 2007, 25, 4487-4501.	3.8	15
15	Association of HIV status with infection by multiple HPV types. <i>Tropical Medicine and International Health</i> , 2018, 23, 1259-1268.	2.3	15
16	Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia. <i>BMC Cancer</i> , 2014, 14, 451.	2.6	14
17	The Prevalence of High-Risk HPV Types and Factors Determining Infection in Female Colombian Adolescents. <i>PLoS ONE</i> , 2016, 11, e0166502.	2.5	14
18	Towards designing a synthetic antituberculosis vaccine: The Rv3587c peptide inhibits mycobacterial entry to host cells. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2401-2409.	3.0	13

#	ARTICLE	IF	CITATIONS
19	Hotspots in Plasmodium and RBC Receptor-Ligand Interactions: Key Pieces for Inhibiting Malarial Parasite Invasion. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4729.	4.1	11
20	Rv1268c protein peptide inhibiting <i>Mycobacterium tuberculosis</i> H37Rv entry to target cells. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6650-6656.	3.0	6
21	Cellâ€Peptide Specific Interaction Can Inhibit <i>Mycobacterium tuberculosis</i> H37Rv Infection. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 946-958.	2.6	6
22	A pre-PEXEL histidine-rich protein II erythrocyte binding peptide as a new way for anti-malarial vaccine development. <i>Biochemical and Biophysical Research Communications</i> , 2007, 360, 149-155.	2.1	5
23	<i>Mycobacterium tuberculosis</i> H37Rv LpqG Protein Peptides Can Inhibit Mycobacterial Entry through Specific Interactions. <i>Molecules</i> , 2018, 23, 526.	3.8	5
24	From a basic to a functional approach for developing a blood stage vaccine against <i>Plasmodium vivax</i> . <i>Expert Review of Vaccines</i> , 2020, 19, 195-207.	4.4	4
25	<i>Plasmodium vivax</i> Pv12 B-cell epitopes and HLA-DR <sup>21*</sup> -dependent T-cell epitopes in vitro antigenicity. <i>PLoS ONE</i> , 2018, 13, e0203715.	2.5	3
26	Specific Binding Peptides from Rv3632: A Strategy for Blocking <i>Mycobacterium tuberculosis</i> Entry to Target Cells?. <i>BioMed Research International</i> , 2019, 2019, 1-13.	1.9	3
27	T Cell Peptides Derived from Invasive Stages of <i>Schistosoma mansoni</i> as Potential Schistosomiasis Vaccine. <i>Journal of Clinical Medicine</i> , 2021, 10, 445.	2.4	1
28	<i>Mycobacterium tuberculosis</i> Rv0292 Protein Peptides Could be Included in a Synthetic Anti-tuberculosis Vaccine. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 2823.	1.9	1
29	Cervical cancer screening programme attendance and compliance predictors regarding Colombiaâ€™s Amazon region. <i>PLoS ONE</i> , 2022, 17, e0262069.	2.5	0